Rear Adm. (ret) Sandra L. Kweder, MD, FACP
Office of New Drugs
Sandra L. Kweder graduated from the University of Connecticut in 1979 and attended the University of North Carolina’s School of Public Health in Chapel Hill. She was commissioned in the U.S. Public Health Service in 1980 upon entering the Uniformed Services University of Health Sciences (USUHS) and retired her uniform in 2013. Following internal medicine training at Walter Reed Army Medical Center she joined the U.S. Food & Drug Administration (FDA) as a medical reviewer in the Division of Antiviral Drugs early in her career to address the growing field of HIV drug development. She has since held a number of positions, including leadership of the Division of Post marketing Surveillance & Epidemiology and the Office of Antimicrobial Products and spent two years on sabbatical at Brown University as a clinical fellow in Obstetric and Consultative Medicine. She has been Deputy Director, Office of New Drugs (OND) in FDA’s Center for Drug Evaluation & Research (CDER) since 2002.
“Working with DIA for me is a real pleasure. Meetings that DIA sponsors really seek to bring all those groups together in one place to share information, ideas, perspectives, and try to find ways to do things better, always in the interest of patients.” - Sandra Kweder, MD
Freda C. Lewis-Hall, MD, FAPA
Chief Medical Officer and
Executive Vice President
As Pfizer’s Chief Medical Officer, Freda Lewis-Hall leads Pfizer Medical, the division devoted to the safe, effective and appropriate use of every Pfizer product, from its first use in a clinical trial until its last use anywhere in the world. She is a member of Pfizer’s Executive Leadership Team and reports to Pfizer’s President and CEO, Ian Read.
Prior to joining Pfizer, Dr. Lewis-Hall was a leader in medical affairs and biomedical product development with Vertex, Pharmacia, Bristol-Myers Squibb and Eli Lilly. She also held leadership, medical and research positions at the National Institute of Mental Health and at the Howard University Hospital and College of Medicine.
In September 2010, Dr. Lewis-Hall was appointed by the Obama Administration to the inaugural Board of Governors for the Patient-Centered Outcomes Research Institute, which is charged with prioritizing and directing a range of research programs to improve the nation’s quality of health care. She also serves on the boards of The Institute of Medicine’s Forum on Drug Discovery, Development, and Translation; The Foundation for the National Institutes of Health; The Harvard Medical School Board of Fellows; the Society for Women’s Health Research; and the American Heart Association’s “Power to End Stroke” initiative. She is a Fellow of the New York Academy of Medicine and the American Psychiatric Association.
Dr. Lewis-Hall was recently chosen as 2011 “Woman of the Year” by the Healthcare Business women’s Association. She has been named as one of the nation’s 75 Most Powerful Women in Business by Black Enterprise magazine and among the 25 Most Influential African-Americans in health care by Black Health magazine.
Dr. Lewis-Hall received her B.A. degree from The Johns Hopkins University and her M.D. from Howard University College of Medicine.
“I look forward to celebrating 50 years of DIA’s achievements with all of you. Knowing that DIA was formed during a golden age of medicine reminds us that the next golden age of medicine, one that I believe is soon within our reach, will present us with challenges never envisioned when DIA was formed in the 1960s. DIA is working on these challenges now, and, central to this task, is dedicated to building the next generation of leaders in healthcare. These are the leaders who will navigate what will surely be the most exciting time ever in biomedical research.” - Freda C. Lewis-Hall, MD, FAPA